BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 21726903)

  • 21. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women.
    Sumino H; Ichikawa S; Ohyama Y; Takahashi T; Saito Y; Nakamura T; Kanda T; Kurabayashi M
    Am J Cardiol; 2005 Jul; 96(1):148-53. PubMed ID: 15979455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
    Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
    Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support.
    White M; Ducharme A; Ibrahim R; Whittom L; Lavoie J; Guertin MC; Racine N; He Y; Yao G; Rouleau JL; Schiffrin EL; Touyz RM
    Clin Sci (Lond); 2006 Apr; 110(4):483-9. PubMed ID: 16402915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists.
    Bedaiwy MA; Mousa NA; Casper RF
    Fertil Steril; 2009 Apr; 91(4 Suppl):1574-7. PubMed ID: 18973892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE; Anania C; Malinak R
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
    Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
    Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation.
    Stabler T; Piette JC; Chevalier X; Marini-Portugal A; Kraus VB
    Arthritis Rheum; 2004 Nov; 50(11):3663-7. PubMed ID: 15529362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity and GnRH action. Report of a case with contribution by peripherally derived estrogens.
    Hansen LM; Batzer FR; Corson SL; Bello S
    J Reprod Med; 1997 Apr; 42(4):247-50. PubMed ID: 9131500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    Scand J Rheumatol; 2009; 38(6):439-44. PubMed ID: 19922018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
    Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
    Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A comparative efficacy study of the preoperative use of GnRH agonists in women with uterine fibromyomas].
    Nikolov A; Karag'ozov I
    Akush Ginekol (Sofiia); 1999; 38(4):38-42. PubMed ID: 10726353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GnRH agonists before surgery for uterine leiomyomas. A review.
    Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
    J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyalinization and cellular changes in uterine leiomyomata after gonadotropin releasing hormone agonist therapy.
    Cohen D; Mazur MT; Jozefczyk MA; Badawy SZ
    J Reprod Med; 1994 May; 39(5):377-80. PubMed ID: 7520497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers.
    Rothenbacher D; Müller-Scholze S; Herder C; Koenig W; Kolb H
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):194-9. PubMed ID: 16239601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist.
    Rein MS; Friedman AJ; Pandian MR; Heffner LJ
    Obstet Gynecol; 1990 Sep; 76(3 Pt 1):388-94. PubMed ID: 2116610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gonadotropin-releasing hormone agonist pretreatment did not decrease postoperative adhesion formation after abdominal myomectomy in a randomized control trial.
    Coddington CC; Grow DR; Ahmed MS; Toner JP; Cook E; Diamond MP
    Fertil Steril; 2009 May; 91(5):1909-13. PubMed ID: 18439584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating levels of soluble E-selectin, P-selectin and intercellular adhesion molecule-1 in patients with juvenile idiopathic arthritis.
    De Benedetti F; Vivarelli M; Pignatti P; Oliveri M; Massa M; Pistorio A; Martini A
    J Rheumatol; 2000 Sep; 27(9):2246-50. PubMed ID: 10990242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is dialysis membrane type responsible for increased circulating adhesion molecules during chronic hemodialysis?
    Mrowka C; Heintz B; Sieberth HG
    Clin Nephrol; 1999 Nov; 52(5):312-21. PubMed ID: 10584995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.